Nuclear localisation of LASP-1 correlates with poor long-term survival in female breast cancer

British Journal of Cancer

Volumn 102, Issue 11, 2010, Pages 1645-1653

  Frietsch, J J ^a   Grunewald, T G P ^b   Jasper, S ^a   Kammerer, U ^a   Herterich, S ^a   Kapp, M ^a   Honig, A ^a   Butt, E ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Department of Pediatrics   (Germany)

Author keywords

Breast cancer; Ki67; LASP 1; P53; PDEF

Indexed keywords

BETA ACTIN; CYTOPLASM PROTEIN; GENE PRODUCT; KI 67 ANTIGEN; PROTEIN LASP 1; PROTEIN P53; PROTEIN PDEF; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER PATIENT; CANCER SURVIVAL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LASP1 GENE; MAJOR CLINICAL STUDY; NUCLEAR LOCALIZATION SIGNAL; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CELL NUCLEUS; CYTOSKELETAL PROTEINS; FEMALE; GENE AMPLIFICATION; HUMANS; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVORS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 77952889009     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605685     Document Type: Article

References (45)

1. Beckerle MC (1997) Zyxin: zinc fingers at sites of cell adhesion. Bioessays 19: 949-957
2. Bieche I, Tomasetto C, Regnier CH, Moog-Lutz C, Rio MC, Lidereau R (1996) Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer. Cancer Res 56: 3886-3890
3. Butt E, Gambaryan S, Gottfert N, Galler A, Marcus K, Meyer HE (2003) Actin binding of human LIM and SH3 protein is regulated by cGMP-and cAMP-dependent protein kinase phosphorylation on serine 146. J Biol Chem 278: 15601-15607
4. Chew CS, Chen X, Parente Jr JA, Tarrer S, Okamoto C, Qin HY (2002) Lasp-1 binds to non-muscle F-actin in vitro and is localized within multiple sites of dynamic actin assembly in vivo. J Cell Sci 115: 4787-4799
5. Dalton LW, Pinder SE, Elston CE, Ellis IO, Page DL, Dupont WD, Blamey RW (2000) Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement. Mod Pathol 13: 730-735
6. Dimova I, Orsetti B, Negre V, Rouge C, Ursule L, Lasorsa L, Dimitrov R, Doganov N, Toncheva D, Theillet C (2009) Genomic markers for ovarian cancer at chromosomes 1, 8 and 17 revealed by array CGH analysis. Tumori 95: 357-366
7. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25: 3994-4008
8. Ehrig T, Abdulkadir SA, Dintzis SM, Milbrandt J, Watson MA (2001) Quantitative amplification of genomic DNA from histological tissue sections after staining with nuclear dyes and laser capture microdissec-tion. J Mol Diagn 3: 22-25
9. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, Watson DK (2003) Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 63: 4626-4631
10. Findlay VJ, Turner DP, Moussa O, Watson DK (2008) MicroRNA-mediated inhibition of prostate-derived Ets factor messenger RNA translation affects prostate-derived Ets factor regulatory networks in human breast cancer. Cancer Res 68: 8499-8506
11. Ghadersohi A, Pan D, Fayazi Z, Hicks DG, Winston JS, Li F (2007) Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res Treat 102: 19-30
12. Godfrey TE, Kim SH, Chavira M, Ruff DW, Warren RS, Gray JW, Jensen RH (2000) Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5 nuclease quantitative reverse transcription-polymerase chain reaction. J Mol Diagn 2: 84-91
13. Grunewald TG, Butt E (2008) The LIM and SH3 domain protein family: structural proteins or signal transducers or both? Mol Cancer 7: 31
14. Grunewald TG, Kammerer U, Kapp M, Eck M, Dietl J, Butt E, Honig A (2007a) Nuclear localization and cytosolic overexpression of LASP-1 correlates with tumor size and nodal-positivity of human breast carcinoma. BMC Cancer 7: 198
15. Grunewald TG, Kammerer U, Schulze E, Schindler D, Honig A, Zimmer M, Butt E (2006) Silencing of LASP-1 influences zyxin localization, inhibits proliferation and reduces migration in breast cancer cells. Exp Cell Res 312: 974-982
16. Grunewald TG, Kammerer U, Winkler C, Schindler D, Sickmann A, Honig A, Butt E (2007b) Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation. Br J Cancer 96: 296-305
17. Grunewald TG, Pasedag SM, Butt E (2009) Cell adhesion and transcrip-tional activity\defining the role of the novel protooncogene LPP. Transl Oncol 2: 107-116
18. Hammarstrom A, Berndt KD, Sillard R, Adermann K, Otting G (1996) Solution structure of a naturally-occurring zinc-peptide complex demonstrates that the N-terminal zinc-binding module of the Lasp-1 LIM domain is an independent folding unit. Biochemistry 35: 12723-12732
19. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70
20. Hirota T, Morisaki T, Nishiyama Y, Marumoto T, Tada K, Hara T, Masuko N, Inagaki M, Hatakeyama K, Saya H (2000) Zyxin, a regulator of actin filament assembly, targets the mitotic apparatus by interacting with h-warts/LATS1 tumor suppressor. J Cell Biol 149: 1073-1086
21. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66
22. Kadrmas JL, Beckerle MC (2004) The LIM domain: from the cytoskeleton to the nucleus. Nat Rev Mol Cell Biol 5: 920-931
23. Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW, Pinkel D (1994) Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 10: 231-243 (Pubitemid 24238430)
24. Keicher C, Gambaryan S, Schulze E, Marcus K, Meyer HE, Butt E (2004) Phosphorylation of mouse LASP-1 on threonine 156 by cAMP-and cGMP-dependent protein kinase. Biochem Biophys Res Commun 324: 308-316
25. Kutay U, Guttinger S (2005) Leucine-rich nuclear-export signals: born to be weak. Trends Cell Biol 15: 121-124
26. Lehmann U, Kreipe H (2001) Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods (San Diego, CA) 25: 409-418
27. Li B, Zhuang L, Trueb B (2004) Zyxin interacts with the SH3 domains of the cytoskeletal proteins LIM-nebulette and Lasp-1. J Biol Chem 279: 20401-20410
28. Mauriac L, Debled M, MacGrogan G (2005) When will more useful predictive factors be ready for use? Breast (Edinburgh, Scotland) 14: 617-623
29. Nakagawa H, Terasaki AG, Suzuki H, Ohashi K, Miyamoto S (2006) Short-term retention of actin filament binding proteins on lamellipodial actin bundles. FEBS Lett 580: 3223-3228
30. Petit MM, Meulemans SM, Van de Ven WJ (2003) The focal adhesion and nuclear targeting capacity of the LIM-containing lipoma-preferred partner (LPP) protein. J Biol Chem 278: 2157-2168
31. Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140
32. Ross JS, Fletcher JA (1999) The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol 9: 125-138
33. Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol (Clifton, NJ) 132: 365-386
34. Salvi A, Bongarzone I, Micciche F, Arici B, Barlati S, De Petro G (2009) Proteomic identification of LASP-1 down-regulation after RNAi urokinase silencing in human hepatocellular carcinoma cells. Neoplasia (New York, NY) 11: 207-219
35. Schreiber V, Moog-Lutz C, Regnier CH, Chenard MP, Boeuf H, Vonesch JL, Tomasetto C, Rio MC (1998) Lasp-1, a novel type of actin-binding protein accumulating in cell membrane extensions. Mol Med 4: 675-687
36. Singletary SE, Connolly JL (2006) Breast cancer staging: working with the sixth edition of the AJCC cancer staging manual. CA Cancer J Clin 56: 37-47; quiz 50-51
37. Sood AK, Saxena R, Groth J, Desouki MM, Cheewakriangkrai C, Rodabaugh KJ, Kasyapa CS, Geradts J (2007) Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. Human Pathol 38: 1628-1638
38. Sun HJ, Bahk YY, Choi YR, Shim JH, Han SH, Lee JW (2006) A proteomic analysis during serial subculture and osteogenic differentiation of human mesenchymal stem cell. J Orthop Res 24: 2059-2071
39. Tan PH, Bay BH, Yip G, Selvarajan S, Tan P, Wu J, Lee CH, Li KB (2005) Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 18: 374-381
40. Tomasetto C, Moog-Lutz C, Regnier CH, Schreiber V, Basset P, Rio MC (1995a) Lasp-1 (MLN 50) defines a new LIM protein subfamily characterized by the association of LIM and SH3 domains. FEBS Lett 373: 245-249
41. Tomasetto C, Regnier C, Moog-Lutz C, Mattei MG, Chenard MP, Lidereau R, Basset P, Rio MC (1995b) Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17. Genomics 28: 367-376
42. Turcotte S, Forget MA, Beauseigle D, Nassif E, Lapointe R (2007) Prostate-derived Ets transcription factor overexpression is associated with nodal metastasis and hormone receptor positivity in invasive breast cancer. Neoplasia (New York, NY) 9: 788-796
43. Turner DP, Findlay VJ, Kirven AD, Moussa O, Watson DK (2008) Global gene expression analysis identifies PDEF transcriptional networks regulating cell migration during cancer progression. Mol Biol Cell 19: 3745-3757
44. Wang B, Feng P, Xiao Z, Ren EC (2009) LIM and SH3 protein 1 (Lasp1) is a novel p53 transcriptional target involved in hepatocellular carcinoma. J Hepatol 50: 528-537
45. Widakowich C, de Azambuja E, Gil T, Cardoso F, Dinh P, Awada A, Piccart-Gebhart M (2007) Molecular targeted therapies in breast cancer: where are we now? Int J Biochem Cell Biol 39: 1375-1387